What we do AstraZeneca Pharma India Limited manufactures, markets, and distributes innovative pharmaceutical products in oncology, cardio-metabolism, respiratory, and rare diseases sectors. |
Founded in 1,979 |
Market share Leading in oncology and biopharmaceuticals with strong presence in diabetes and respiratory markets. |
Problem solved Addresses critical unmet medical needs in cancer, cardiovascular diseases, diabetes, respiratory illnesses, and rare disorders. |
Top clients or who we serve Healthcare providers, hospitals, specialists, and patients across India; primarily B2B with growing patient focus. |
Key management Dr. Sanjeev Kumar Panchal (Managing Director) with global pharma experience; leadership with strong industry credentials. |
Our journey and innovations Founded in 1979, expanded manufacturing and R&D capabilities; launched breakthrough oncology and biopharmaceutical therapies; integrated globally. |
Where we operate Primarily India with exports outside India contributing modestly; distribution partnerships expand reach. |
Top products or what we offer Key products include Tagrisso, Enhertu, Imfinzi, Brilinta, Fasenra, Breztri Aerosphere, Soliris for advanced therapies. |
Top brands Tagrisso (#1 lung cancer brand India), Enhertu (top 10 oncology), Brilinta (leading oral antiplatelet), Fasenra (#1 biologic in asthma). |
Raw materials needed Active pharmaceutical ingredients, excipients, and packaging materials sourced from specialized suppliers. |
Raw materials supplier Sourced globally from approved vendors aligned with quality and regulatory standards. |
Recurring vs cyclical contribution Revenue driven by recurring pharmaceutical product sales with some growth from newer therapeutic launches. |
Our industry position Strong market leadership in oncology and specialty pharma segments; innovative pipeline supports leadership. |
Financial highlights FY 2024-25 revenue Rs. 17,569 million; net profit Rs. 1,157 million; 33% sales growth year-on-year. |
Geographical revenue split India accounts for ~94% revenue; exports contribute approximately 6%. |
Order book - |
Whats driving growth Innovation in oncology, diabetes, respiratory therapies; strategic partnerships and expanding indications. |
Our future plans Focus on new product launches, pipeline advancement, enhanced access programs and manufacturing optimization. |
Our green promise Committed to sustainability, reducing carbon footprint, ethical practices, and health equity initiatives. |
Our people and values 802 employees fostering inclusive, innovative, and performance-driven culture with strong talent development. |
Key challenges ahead Pricing regulations, generic competition, supply chain challenges, and evolving healthcare policies. |
Interesting facts First COPD therapy and pioneering biologics launched recently; active in rare disease awareness and patient support. |
Risks and strategy Mitigates regulatory, competitive, and operational risks through robust compliance, innovation, partnerships, and patient focus. |
